Lixte Biotechnology presents preliminary LB100 results

Lixte Biotechnology (LIXT) announced the presentation of preliminary results for a clinical trial testing the combination of Lixte’s proprietary compound LB100 in combination with Dostarlimab at the 2026 Conference of the Society of Gynecological Cancer, April 10-13, in San Juan, Puerto Rico. At a median follow-up length of 12 months, median OS has not been reached. However, OS probability was 0.84 at 6 months and 0.69 at 12 months. The Disease Control Rate was 40%. Specifically, prior investigation reported markedly prolonged overall survival with ICB in patients with PPP2R1A-mutant OCCC. This suggested that reducing PP2A pharmacologically with LB-100 may enhance the anti-tumor effect of the PD-1 blocking monoclonal antibody, dostarlimab-gxly, in patients with Ovarian Clear Cell Carcinoma lacking the genetic reduction in PP2A.